AbCellera Biologics (ABCL) PT Raised to $12 at Truist Securities May 22, 2026 09:20AM
Increasing unusual put option volume: TIGR XLI EXE INFQ ABCL FUTU INTU CMPS ADMA May 21, 2026 09:57AM
AbCellera Biologics (ABCL) PT Raised to $11 at Cantor Fitzgerald Post Q1 Print, Trial Data May 12, 2026 09:27AM
AbCellera Biologics (ABCL) PT Raised to $8 at Stifel on Positive Data for ABCL635 May 12, 2026 07:27AM
AbCellera (ABCL) Tops Q1 EPS by 1c May 11, 2026 04:06PM


May 5, 2026 06:08AM Cantor Fitzgerald Starts AbCellera Biologics (ABCL) at Overweight
Apr 15, 2026 10:01AM Truist Securities Reiterates Buy Rating on AbCellera Biologics (ABCL)
Apr 15, 2026 10:01AM Truist Securities Reiterates Buy Rating on AbCellera Biologics (ABCL)
Apr 9, 2026 04:08PM Jones Trading Starts AbCellera Biologics (ABCL) at Buy
Feb 24, 2026 04:15PM AbCellera (ABCL) Reports FY Loss of $0.49
Feb 14, 2026 10:00AM Which healthcare stocks are at risk from AI and which to buy
Dec 18, 2025 09:01AM AbCellera settles patent litigation with Bruker for $36 million
Nov 7, 2025 06:08AM Leerink Partners Downgrades AbCellera Biologics (ABCL) to Market Perform
Nov 6, 2025 04:10PM AbCellera (ABCL) Misses Q3 EPS by 5c
Aug 13, 2025 10:05AM Benchmark Reiterates Hold Rating on AbCellera Biologics (ABCL)
Aug 7, 2025 04:23PM AbCellera (ABCL) Tops Q2 EPS by 2c
Jul 7, 2025 06:20AM Leerink Partners Assumes AbCellera Biologics (ABCL) at Outperform, PT $5
May 30, 2025 01:00PM AbCellera (ABCL) Cleared to Initiate a Phase 1 Clinical Trial of ABCL575 in Canada
May 16, 2025 10:06AM Truist Slashes AbCellera Biologics (ABCL) Stock PT from $28 to $10
May 14, 2025 05:00PM AbCellera (ABCL) Receives Authorization from Health Canada to Initiate the Phase 1 Clinical Trial of ABCL635 for Vasomotor Symptoms Due to Menopause
May 12, 2025 03:30PM AbCellera's (ABCL) Microfluidic Cell Culture Patent Affirmed Valid by the U.S. Court of Appeals for the Federal Circuit
May 8, 2025 04:05PM AbCellera (ABCL) Misses Q1 EPS by 1c
Apr 29, 2025 03:01PM AbCellera (ABCL) Presents Data Showing Preclinical Efficacy of PSMA x CD3 T-Cell Engagers
Mar 3, 2025 09:41AM Benchmark Reiterates Hold Rating on AbCellera Biologics (ABCL)
Feb 27, 2025 04:19PM AbCellera (ABCL) reported revenue at $5.1 million
Jan 13, 2025 09:09AM AbCellera (ABCL) Expands Collaboration with AbbVie (ABBV) to Develop Novel T-Cell Engagers for Oncology
Nov 5, 2024 08:14AM AbCellera Biologics (ABCL) PT Lowered to $5 at BMO Capital
Nov 4, 2024 04:08PM AbCellera (ABCL) Tops Q3 EPS by 1c
Aug 23, 2024 11:57AM KeyBanc Reiterates Overweight Rating on AbCellera Biologics (ABCL)
Aug 20, 2024 09:15AM Benchmark Downgrades AbCellera Biologics (ABCL) to Hold
Aug 6, 2024 04:08PM AbCellera (ABCL) Tops Q2 EPS by 1c
Jul 31, 2024 09:01AM AbCellera (ABCL) and Lilly Expand Collaboration to Develop Antibody Medicines
Jun 28, 2024 10:34AM TD Cowen Reiterates Buy Rating on AbCellera Biologics (ABCL)